Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sage Therapeutics stock drops
Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide
Sage Therapeutics said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a late-stage trial, sending its shares down 10% in premarket trading.
Sage Therapeutics’ stock slides after biotech says it will cease development of Alzheimer’s treatment
Sage Therapeutics Inc.’s stock tumbled 12.8% early Tuesday, after the company said a mid-stage trial of a treatment for mild cognitive impairment and mild dementia in Alzheimer’s disease failed to meet its main goal.
Sage Therapeutics Stock Down Almost 40% in 3 Months: Here's Why
Sage Therapeutics, Inc. SAGE is focused on developing life-changing brain health medicines. In July, Sage Therapeutics and partner Biogen BIIB announced top-line data from the phase II KINETIC 2 study,
Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares tank
Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it did not meet the main goal in a mid-stage trial, sending its shares down about 12% to $5.
Sage Therapeutics Shares Fall Premarket After Alzheimer's Setback
Sage Therapeutics shares fell more than 10% in premarket trading Tuesday after the latest setback for the biopharmaceutical company's dalzanemdor drug candidate. Shares of Sage, which closed Monday at $6.72, were recently down 12% to $5.89 in premarket trading.
Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results from its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for the treatment of mild cognitive
1h
SAGE Therapeutics: Downgrade to Sell Amid Pipeline Setbacks and Reduced Price Target
Bank of America Securities analyst Tazeen Ahmad has reiterated their bearish stance on SAGE stock, giving a Sell rating on October 4. Tazeen ...
FierceBiotech
1d
Sage scraps Alzheimer's program as dalzanemdor goes 0 for 2, leaving hopes resting on Huntington's
Sage Therapeutics has seen another clinical trial go up in smoke. | Sage Therapeutics has seen another clinical trial go up ...
pharmaphorum
6h
Sage takes another hit as Alzheimer's drug is canned
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...
BioSpace
1d
Sage Suffers Third Neuro Stumble in Six Months With Disappointing Mid-Stage Alzheimer’s Readout
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
18h
Hold Rating on SAGE Therapeutics Amid Clinical Trial Uncertainties
Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating today. Ami Fadia has given his Hold rating ...
1d
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Tuesday, Sage Therapeutics, Inc. (NASDAQ:SAGE) released topline results from the Phase 2 LIGHTWAVE study to evaluate the ...
2d
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...
5d
on MSN
Sage stock slides as RBC cuts rating to Sell on trial results concerns
RBC Capital Markets cut its rating on SAGE Therapeutics Inc (NASDAQ:SAGE) from Sector Perform to Underperform (Sell), due to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Alzheimer's disease
dalzanemdor
Mild cognitive impairment
Phases of clinical research
Feedback